Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.3%

2 terminated/withdrawn out of 38 trials

Success Rate

94.7%

+8.2% vs industry average

Late-Stage Pipeline

37%

14 trials in Phase 3/4

Results Transparency

22%

8 of 36 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1

16(43.2%)

Phase 3

14(37.8%)

Phase 2

5(13.5%)

N/A

2(5.4%)

37Total

Phase 1(16)

Phase 3(14)

Phase 2(5)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT06507566Not ApplicableCompleted

Evaluating Technologies for Point-of-Care Blood Collections by Patients

Role: lead

NCT00782431Phase 3Completed

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Role: lead

NCT00800605Phase 3Completed

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Role: lead

NCT01773928Phase 3Completed

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

Role: lead

NCT04592549Phase 1Completed

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

Role: lead

NCT04171115Phase 1Completed

Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

Role: lead

NCT00566345Phase 3Completed

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Role: lead

NCT01320696Phase 1Completed

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Role: lead

NCT05142527Phase 2Withdrawn

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

Role: lead

NCT04679623Phase 1Completed

Study of Midazolam in Healthy Adults

Role: collaborator

NCT04705844Phase 3Withdrawn

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Role: lead

NCT01157702Phase 3Completed

Yearly Strain Variation Study, 2010/2011

Role: lead

NCT03046550Phase 1Completed

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

Role: lead

NCT01258062Phase 1Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Role: lead

NCT00959465Phase 1Completed

A/H1N1 Immunogenicity and Safety in Adults

Role: lead

NCT00530660Phase 2Completed

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Role: lead

NCT01382329Phase 2Completed

H5N1 Vaccine Study in Japanese Adults

Role: lead

NCT00161837Phase 2Completed

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Role: lead

NCT00717834Phase 1Completed

Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine

Role: lead

NCT01063088Phase 3Completed

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Role: lead